NCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
Clinical Trials
8 trialsNCT03011372 2025-11-18
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Incyte Corporation
Phase 2 Completed
NCT02872714 2025-08-14
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
Incyte Corporation
Phase 2 Completed
NCT02924376 2025-08-14
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
Incyte Corporation
Phase 2 Completed
NCT05253807 2025-08-05
FIGHT-210
Incyte Corporation
Phase 2 Completed
NCT04256980 2024-05-30
Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Completed
NCT04258527 2021-07-23
Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT03235570 2020-05-29
A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)
Incyte Corporation
Phase 1 Completed